Hepatitis C treatment outcomes in Australian clinics

Medical Journal of Australia

Volumn 196, Issue 10, 2012, Pages 633-637

  Gidding, Heather F ^a   Law, Matthew G ^a   Amin, Janaki ^a   Ostapowicz, George ^b   Weltman, Martin ^c   Macdonald, Graeme A ^d   Sasadeusz, Joe J ^e   Haber, Paul A W ^f   George, Jacob ^g   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c NEPEAN HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUSTRALIAN; BODY MASS; ETHNIC GROUP; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE; AUSTRALIA; CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; GENETICS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MIXED INFECTION; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; AUSTRALIA; BODY MASS INDEX; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84865083728     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10014     Document Type: Article

References (25)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
4. McHutchison JG, Lawitz EJ, Shiffman ML, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
5. Kumar D, Wallington-Beddoe C, George J, et al. Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 2003; 178: 267-271.
6. Gheorghe L, Iacob S, Sporea I, et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 23-29.
7. Fattovich G, Covolo L, Pasino M, et al; Italian Hepatitis C Cohort Study Collaborative Group. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011; 31: 66-74.
8. Mauss S, Hueppe D, John C, et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat 2011; 18: e81-e90.
9. Hansen N, Obel N, Christensen PB, et al; Danish Database for Hepatitis B and C (DANHEP) group. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011; 11: 177.
10. Gidding HF, Law MG, Amin J, et al; ACHOS investigator team. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194: 398-402.
11. Department of Health and Ageing. National hepatitis C resource manual. 2nd ed. Canberra: Commonwealth of Australia, 2008. http://www. health.gov.au/internet/main/publishing.nsf/ content/phd-hepc-manual-2008 (accessed May 2012).
12. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
14. Chung RT, Andersen J, Volberding P, et al; AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
15. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al; APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
16. Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010; 52: 864-874.
17. Honda A, Matsuzaki Y. Cholesterol and chronic hepatitis C virus infection. Hepatol Res 2011; 41: 697-710.
18. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
19. Pockros PJ, Hamzeh FM, Martin P, et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 2010; 52: 1193-1200.
20. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736.
21. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
22. Schlütter J. Therapeutics: new drugs hit the target. Nature 2011; 474: S5-S7.
23. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
24. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
25. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011; 31 Suppl 1: 62-67.